KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Receivables (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Receivables data on record, last reported at $4.7 billion in Q1 2025.

  • For Q1 2025, Receivables fell 11.04% year-over-year to $4.7 billion; the TTM value through Mar 2025 reached $4.7 billion, down 11.04%, while the annual FY2025 figure was $4.7 billion, 13.29% down from the prior year.
  • Receivables reached $4.7 billion in Q1 2025 per TAK's latest filing, down from $5.2 billion in the prior quarter.
  • Across five years, Receivables topped out at $7.4 billion in Q1 2021 and bottomed at $503.8 million in Q1 2023.
  • Average Receivables over 5 years is $3.7 billion, with a median of $4.7 billion recorded in 2025.
  • Peak YoY movement for Receivables: tumbled 91.49% in 2022, then soared 937.5% in 2024.
  • A 5-year view of Receivables shows it stood at $7.4 billion in 2021, then crashed by 91.49% to $629.4 million in 2022, then dropped by 19.96% to $503.8 million in 2023, then skyrocketed by 937.5% to $5.2 billion in 2024, then dropped by 11.04% to $4.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $4.7 billion in Q1 2025, $5.2 billion in Q1 2024, and $503.8 million in Q1 2023.